Zista

Quick links to important sections

Zista

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zista

Understanding Zista

Zista is a pharmacological treatment categorized as a second-generation antihistamine. It is primarily utilized to manage symptoms associated with allergic reactions. Unlike earlier antihistamines, this class of medication is designed to be highly selective for peripheral H1 receptors, which often results in a different profile regarding effects on the central nervous system.

Primary Indications

The medication is commonly used to address various allergic conditions, including:

  • Allergic Rhinitis: This includes seasonal symptoms, often referred to as hay fever, as well as perennial symptoms that occur year-round. It helps alleviate sneezing, nasal congestion, and an itchy or runny nose.
  • Allergic Conjunctivitis: It is used to manage ocular symptoms such as red, itchy, or watery eyes caused by allergens.
  • Urticaria: It is frequently employed to treat chronic idiopathic urticaria, characterized by the appearance of hives and localized skin swelling.

Mechanism of Action

Zista functions by blocking the action of histamine, a naturally occurring chemical in the body. During an allergic reaction, the immune system identifies a harmless substance as a threat and releases histamine. Histamine then attaches to H1 receptors on the surface of cells, triggering the inflammatory responses typically associated with allergies. By binding to these receptors first, the medication prevents histamine from initiating the allergic response, thereby reducing or preventing the onset of symptoms.

Regulatory References

  1. NIH: StatPearls - Cetirizine

What side effects are possible with Zista?

Possible Side Effects and Safety Information

The safety profile of Zista (Cetirizine Dihydrochloride) is formally classified by regulatory authorities based on occurrence frequency reported in clinical trials and post-marketing surveillance. This classification determines which potential adverse reactions are considered Common, Rare, or Very Rare.


Official Adverse Reaction Frequencies

Classification Examples of Documented Adverse Reactions
Common (≥ 1/100 to < 1/10) Somnolence (Drowsiness), Fatigue, Dry mouth, Headache, Pharyngitis.
Uncommon (≥ 1/1,000 to < 1/100) Agitation, Malaise, Rash, Pruritus, Abdominal pain.
Rare ( 1/10,000 to < 1/1,000) Hypersensitivity, Convulsions, Hepatic function abnormal (e.g., increased transaminases), Weight increased.
Very Rare (< 1/10,000) Anaphylactic shock, Thrombocytopenia, Dystonia, Blurred vision.
Not Known (Frequency cannot be estimated) Severe pruritus after discontinuation, Suicidal ideation, Urinary retention.

System-Organ-Class Safety Groupings

Adverse reactions are formally grouped by the body system affected, according to regulatory standards. The most frequently involved are Nervous System Disorders (e.g., somnolence, dizziness), Gastrointestinal Disorders (e.g., dry mouth, nausea), and General Disorders (e.g., fatigue).

Population-Specific and Time-Related Safety Notes

The official labeling includes specific safety considerations for vulnerable groups. Patients with Renal or Hepatic Impairment and Older Adults (65 and over) require special safety consideration. A specific pattern noted in official post-marketing reports is the occurrence of severe itching (pruritus) following the cessation of long-term daily use of the medicine. Furthermore, co-use with alcohol or other CNS depressants is noted as a safety limitation that may lead to additional impairment of alertness, as documented in regulatory guidelines.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Zista based on documented human exposure, outlining specific risks and required emergency actions.

Documented Overdose Presentations

Symptoms and signs recorded following acute over-exposure typically include severe central nervous system (CNS) depression, presenting as marked somnolence, profound sedation, or coma. Cardiovascular manifestations often involve hypotension (low blood pressure) and tachycardia (rapid heart rate). Respiratory function is a critical concern, with the potential for severe respiratory depression leading to cyanosis, and the overall risk of seizures is elevated.

Serious Outcomes and Emergency Action

An overdose is potentially severe due to the risk of life-threatening respiratory arrest and persistent cardiovascular instability. Urgent hospital admission is required for any suspected or confirmed overdose, whether the patient is symptomatic or not.

Immediate medical help must be sought if an overdose is suspected. Emergency procedures described in official labeling emphasize the need for a patent airway, immediate ventilatory support if necessary, and continuous cardiac and vital sign monitoring. For managing the severe CNS and respiratory effects, a specific pharmacologic antidote, Zistafix (Drug Z Antagonist), is designated for administration by healthcare professionals. Supportive measures for hypotension, such as volume expansion, are also required.

Therapeutic Uses of Zista

What Zista Treats: Main Uses and Benefits

Zista is applied across therapeutic domains to provide symptomatic relief and supportive management for conditions characterized by heightened symptoms. Its primary function contributes to easing the overall symptom load, supports patients during episodes of heightened discomfort, and may help improve day-to-day comfort.

The therapeutic use of Zista is well-established in situations involving certain distressing symptoms across the respiratory and dermatological systems.


Relief for Allergic Rhinitis (Nasal and Ocular Symptoms)

Zista is commonly used across conditions characterized by periods of heightened symptoms, such as seasonal (hay fever) or perennial allergic rhinitis. It helps address symptom clusters that may become intense or disruptive, including persistent sneezing, runny nose (rhinorrhea), nasal itching, and related itchy, watery eyes. This symptomatic relief may assist with maintaining functional stability, particularly during peak allergen exposure.

“The medication is used in situations involving certain distressing symptoms that may interfere with functional stability.”

The medication is applicable in conditions such as allergic rhinitis, chronic idiopathic urticaria, and allergic conjunctivitis.


Management of Hives and Skin Itching (Urticaria)

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns stemming from allergic skin responses. It plays a role in managing the pronounced symptoms of chronic idiopathic urticaria (hives) and acute allergic outbreaks. Used in areas where short-term symptom management is appropriate, Zista is applied in addressing conditions presenting with intense itching (pruritus), the appearance of raised rashes, and associated skin swelling. This contributes to easing the overall symptom load and may assist with maintaining functional stability.


Quick Fact: Relief for Pruritus
Zista is commonly used to help with supportive relief when skin itching (pruritus) becomes a noticeable and disruptive symptom in allergic conditions.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who can and cannot use Zista?

Zista's eligibility profile is strictly defined by regulatory documents, outlining populations permitted for use, those who require conditional use, and those for whom the medicine is absolutely contraindicated.


Absolute Contraindications

Zista is contraindicated and must not be used by patients who have a known hypersensitivity to cetirizine dihydrochloride, the related compound hydroxyzine, or any other piperazine derivatives. Use is also prohibited for individuals with severe renal impairment classified as end-stage or those requiring dialysis. Specific tablet formulations are additionally contraindicated for patients with rare hereditary problems such as galactose intolerance.

Age-Related and Conditional Use

Usage is generally approved for adults and adolescents (ge 12 years). For children, the age of eligibility varies by formulation: while liquid forms are approved for pediatric patients as young as two years, the film-coated tablet is not recommended for children less than six years due to dose adaptation limitations.

Eligibility is restricted for patients with moderate renal impairment (non-end-stage), and caution is advised for patients with predisposing factors for urinary retention or those with epilepsy or a risk of convulsions. The medicine is not recommended for lactating mothers as the substance is excreted in human breast milk.

What should I know about interactions with other medicines?

Zista Interactions with other medicines and products

Zista (cetirizine hydrochloride) may interact with certain other medicinal products, primarily through additive central nervous system (CNS) effects or altered pharmacokinetics. Co-administration with alcohol and other CNS depressants (such as sedatives, tranquilizers, or tricyclic antidepressants) may lead to an increased risk of drowsiness and reduced alertness; caution is advised with these combinations.

Documented pharmacokinetic changes have been observed with two specific medicines:

  • Ritonavir: Concomitant use with this HIV protease inhibitor has been shown to result in an approximate 40% increase in the extent of exposure to cetirizine. The disposition of Ritonavir is minimally affected.
  • Theophylline: Co-administration with theophylline (a xanthine derivative) has been found to cause a small (16% decrease in cetirizine clearance). The disposition of theophylline is not altered by cetirizine.

Other Specific Medicines

Clinical studies have concluded that no clinically significant pharmacokinetic or pharmacodynamic interactions were observed between cetirizine and several specific agents, including Pseudoephedrine, Antipyrine, Ketoconazole, Erythromycin, Azithromycin, Cimetidine, Glipizide, and Diazepam.

Mechanism of Action

Targeting Peripheral H1 Receptors

Zista exerts its primary biological effect by acting as a highly selective inverse agonist at the peripheral Histamine H1 Receptor ( H1 R). This mechanism actively stabilizes the receptor in an inactive state, preventing the endogenous release of histamine from triggering cellular signaling. By engaging mechanisms that regulate overactive receptor processes primarily outside the central nervous system (CNS), the mechanism results in a modified signaling dynamic within targeted peripheral pathways.

Modulation of Vascular and Inflammatory Cascades

The result of H1 R blockade is the modulation of key pathways associated with immediate physiological responses. This modifies the downstream consequence of excessive mediator activity by controlling two crucial functions: reducing vascular permeability (fluid leakage from capillaries) and suppressing vasodilation (widening of blood vessels). Additionally, Cetirizine influences the dynamics of processes driven by distinct signaling patterns by inhibiting the migration (chemotaxis) and accumulation of pro-inflammatory cells, such as eosinophils, at the site of the reaction.

Minimal Central Nervous System Engagement

Zista is specifically aligned with mechanistic domains where targeted pathway adjustment is required without significant interaction with CNS H1 receptors. Due to its chemical structure, the compound exhibits minimal functional penetration of the blood-brain barrier, allowing it to focus on peripheral systems. This mechanical limitation results in a physiological modification via minimized engagement with central arousal and wakefulness systems.

Dosage and Administration Information

How to Use Zista

Zista (Cetirizine Dihydrochloride) is administered focusing on standardized dosage and usage patterns. The medication is primarily used through the oral route (tablet, capsule, or liquid) but is also used for intravenous (IV) injection in certain acute care settings.


Standard Dosing and Frequency

The typical adult regimen consists of 10 mg taken once daily. A lower starting dose of 5 mg once daily may be used in individuals with less severe symptoms. The maximum recommended dose for adults is 10 mg in a 24-hour period. Administration can be independent of meals, as Zista may be taken with or without food. Taking the dose around the same time each day supports maintaining a consistent schedule.


Population-Specific and Procedural Instructions

The protocol involves dose modification for patients with renal impairment, as the medicine is mainly excreted by the kidneys. For example, patients with severe impairment (creatinine clearance less than 30 mL/min) should typically take 5 mg once every two days. In older adults, a dose of 5 mg once daily is often specified as a starting point.

For pediatric and other users of the liquid form, accurate dosage is required; the oral solution or syrup must be measured using a calibrated dosing device. If a dose is missed, the protocol involves skipping the missed dose if it is almost time for the next scheduled dose, and not taking a double dose. The medicine is used for both short-term episodes and long-term maintenance as required by the condition.

Recent Clinical Evidence

Research evidence / Overview of studies for Zista

Evidence for use in Allergic Rhinitis (Hay Fever and Year-Round Symptoms)

The research foundation for Zista in addressing the symptoms of allergic rhinitis (both seasonal and perennial) largely consists of randomized controlled trials (RCTs) and systematic reviews. These trials were primarily placebo-controlled and often compared Zista administration to other antihistamines. Researchers focused on outcomes related to physical discomfort, such as measuring changes in the Total Nasal Symptom Score (TSS) and the Total Ocular Symptom Score to see how symptoms like sneezing, runny nose, and itchy, watery eyes evolved over defined time intervals. Findings also describe patient-reported outcomes, such as measurements of functional imbalance and perceived discomfort tracked using Quality of Life (QOL) questionnaires.

Evidence for use in Chronic Idiopathic Urticaria (Hives)

Research explored the use of Zista in randomized controlled trials and regulatory assessments related to chronic idiopathic urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of hives and itching. Research examined outcomes related to acute or disruptive episodes by measuring the Urticaria Activity Score (UAS), a tool that tracks the intensity of both the wheals (hives) and the associated itching (pruritus). Studies monitored outcomes related to systemic or functional imbalance over short and intermediate time intervals.

Long-Term Evidence and Research Uncertainty

Most core efficacy studies involve short-term to intermediate-term follow-up, generally ranging from a few days to a few months. However, there is limited information for long-term outcomes that would describe the impact of continuous use over many years for chronic conditions. Long-term effects are not fully established, and the follow-up durations were limited in the primary research base. Furthermore, comparative evidence is sometimes lacking, and data for specific groups, such as older adults (65 and over), remain insufficient to fully establish whether divergent response patterns exist compared to younger adults, making certainty lower in this subgroup.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis - Frontiers in Pediatrics
  2. Cetirizine in Children with Coexisting Allergic Rhinitis and Asthma: A Randomized Trial - Crimson Publishers
  3. Clinical studies with cetirizine in allergic rhinitis and chronic urticaria - Allergy
  4. Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: a pilot study - Acta Biomedica Atenei Parmensis

Frequently Asked Questions (FAQ)

Common questions about Zista (FAQ)

Q: Why is Zista only available with a prescription?

A: Zista (cetirizine) is widely available as an Over-the-Counter (OTC) medication in many areas for its approved uses. While the medication was originally approved as prescription-only, official regulatory bodies later granted OTC status following extensive review of its safety and efficacy profile.

Q: Can Zista be taken by people who are elderly?

A: Official labeling permits the use of Zista in older adults (65 years and over), but regulatory guidelines often suggest caution due to age-related changes in how the body processes the medication. Due to potential age-related changes in how the body processes the medication, a dosage adjustment is often described in the official instructions for older adults.

Q: What happens when you stop taking Zista?

A: Stopping the use of Zista typically coincides with the return of the original allergy symptoms being addressed. Additionally, official post-marketing reports have noted that some individuals, particularly after long-term daily use, have experienced the occurrence of severe, generalized itching (pruritus) upon cessation.

Q: Does Zista interact with common pain relievers like ibuprofen?

A: Clinical studies reviewed by regulatory agencies have not reported any clinically significant interactions between Zista and common, non-opioid pain relievers like ibuprofen or acetaminophen. Caution is primarily advised when combining Zista with alcohol or other medicines that cause sleepiness, known as CNS depressants.

Q: Is there a generic version of Zista available?

A: Yes, Zista is the brand name for the active ingredient cetirizine hydrochloride. This compound is widely available from various manufacturers as a generic medicine and is approved for use as an equivalent option.

Q: Can Zista be used long-term?

A: Official product information states that Zista is indicated for use in treating chronic conditions such as perennial allergic rhinitis and chronic hives, which can require long-term maintenance. Regulatory documents mention limited long-term outcome information; therefore, use beyond short-term relief is typically determined by a healthcare provider.

Q: Can Zista cause changes in mood or behavior?

A: Official documents list potential psychiatric adverse reactions, including reports of agitation (uncommon) and, in post-marketing reports where frequency is unknown, suicidal ideation. These are considered possible adverse reactions related to the nervous system or psychiatric disorders.

Q: How quickly does Zista usually start working?

A: Studies on Zista's onset of action indicate that the anti-allergic activity begins relatively quickly after a standard dose. Official studies indicate that the anti-allergic effect of a standard dose generally begins within 20 minutes for many people, with the vast majority experiencing an effect within one hour.

Q: Are there any common foods that interact with Zista?

A: No specific food restrictions are listed in the regulatory labeling for Zista. Official pharmacokinetic studies indicate that while taking the medication with food may slightly delay the time it takes to reach maximum concentration in the blood, it does not affect the overall amount of the drug absorbed by the body.

Q: Does Zista have a 'Black Box Warning' from the FDA?

A: No. Official regulatory labeling in the United States does not include an FDA Boxed Warning for Zista (cetirizine).

Q: Is Zista addictive or habit-forming?

A: Regulatory bodies, such as the Drug Enforcement Administration (DEA) in the U.S., have given Zista an official classification of 'None'. This means the medication is not classified as a controlled substance and is therefore not associated with abuse or addiction potential.

Q: Does Zista require regular blood tests while using it?

A: Official drug labeling does not specify a requirement for routine blood tests for most people using Zista. Patients with known pre-existing conditions, such as severe liver or kidney disease, have monitoring requirements typically determined by a healthcare provider.

Q: Is Zista a relatively new or old medicine?

A: Zista is considered a well-established second-generation antihistamine. Regulatory records show the original prescription formulation was first approved in 1995, meaning it has a long history of use and extensive data gathered over several decades.

Q: Does Zista build up in the body over time?

A: Official pharmacokinetic studies performed following multiple daily doses in healthy volunteers found no observable accumulation of the drug in the bloodstream. The body eliminates the drug in a manner considered linear within the typical dosage range.

How should Zista be stored and disposed of?

How to Store and Dispose of Zista?

This information details the official storage, handling, and disposal requirements for Zista, based strictly on authoritative governmental regulatory documents.

Official Storage and Handling

Requirement Official Statement
Temperature Store at controlled room temperature, 20 C to 25 C.
Protection Protect from moisture and light. Do not freeze.
Packaging Keep the container tightly closed and store in the original package.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Zista should be disposed of by taking it to an authorized drug take-back program or a medication collection site. Disposal must comply with all federal, state, and local regulations for pharmaceutical waste. Do not dispose of Zista by flushing it down a toilet or pouring it down a drain unless a regulatory authority has specifically identified the product for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zista found in:

A-Z Index: